Top Suppliers:I want be here


23103-35-7

23103-35-7 structure
23103-35-7 structure
  • Name: myo-Inositol Trispyrophosphate Hexasodium Salt
  • Chemical Name: ITTP Hexasodium Salt
  • CAS Number: 23103-35-7
  • Molecular Formula: C6H6Na6O21P6
  • Molecular Weight: 737.88000
  • Catalog: Research Areas Cancer
  • Create Date: 2016-01-16 09:10:39
  • Modify Date: 2024-01-17 03:38:23
  • myo-Inositol trispyrophosphate (ITPP) hexasodium, a modifier of haemoglobin, is an allosteric effector that reduces the oxygen‐binding affinity of haemoglobin and facilitates the release of oxygen by red blood cells. myo-Inositol trispyrophosphate can reverse hypoxia, control tumor growth and improve chemotherapy response[1][2][3].

Name ITTP Hexasodium Salt
Synonyms myo-Inositol Trispyrophosphate Hexasodium Salt
ITPP SODIUM SALT
Description myo-Inositol trispyrophosphate (ITPP) hexasodium, a modifier of haemoglobin, is an allosteric effector that reduces the oxygen‐binding affinity of haemoglobin and facilitates the release of oxygen by red blood cells. myo-Inositol trispyrophosphate can reverse hypoxia, control tumor growth and improve chemotherapy response[1][2][3].
Related Catalog
In Vitro myo-Inositol trispyrophosphate hexasodium (10 mmol/L; 2 hours) significantly inhibits OCR in all six cell lines (FSaII, SiHa, MDA‐MB‐231, NT2, 9L‐glioma and rhabdomyosarcoma) [2].
In Vivo myo-Inositol trispyrophosphate hexasodium (2 g/kg weekly; IP; 7weeks) sustains its significant effect on life prolongation[1]. myo-Inositol trispyrophosphate hexasodium (1.5 g/kg weekly; IV; for 8 weeks) remains metastasis-free on pancreatic carcinomas in immunocompetent male Lewis rats weighing 120-150 g with DSL-6A/C1 cells. myo-Inositol trispyrophosphate hexasodium restores the pO2 pressure in tumors reducing hypoxia-inducible and proangiogenic factors[1]. myo-Inositol trispyrophosphate hexasodium (2 g/kg; once daily for 2 days) shows the most elevated tumour oxygenation at 2 hours in four mouse tumour models (mouse fibrosarcoma FSaII implanted in C3H mice, mouse mammary tumour NT2 in FVb/Nrj mice, human breast cancer MDA‐MB‐231 in NMRI nude mice and human cervix squamous cell carcinoma SiHa in NMRI nude mice) and two rat tumour models (rat 9L‐glioma in Fischer F344 rats and rat rhabdomyosarcoma in WAG/Rij rats)[1]. Animal Model: Nude mice (20 g) with MiaPaCa-2 or DSL-6A/C1 cells[1] Dosage: 2 g/kg (weekly) Administration: IP; weekly; 7weeks Result: Sustained its significant effect on life prolongation.
References

[1]. Zahary Raykov, et al. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. Int J Cancer. 2014 Jun 1;134(11):2572-82.

[2]. Ly-Binh-An Tran, et al. Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models. J Cell Mol Med. 2019 Mar;23(3):1908-1916.

[3]. Marta Oknińska, et al. Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP)-enhancement of oxygen delivery by red blood cells. J Cell Mol Med. 2020 Feb;24(3):2272-2283.

Molecular Formula C6H6Na6O21P6
Molecular Weight 737.88000
Exact Mass 737.72100
PSA 382.71000
LogP 2.63340